... and showed that an inhibitor of ATX increases paclitaxel sensitivity of resistant cancer cells [ 25 ]. © The Authors Journal compilation © 2012 Biochemical Society 2012 autotaxin cancer drug discovery lysophosphatidic acid (LPA) 4-pentadecylbenzylphosphonic acid (4-PBA) therapy ATX...

...) lysophosphatidic acid (LPA) phosphatidic acid (PA) prostate cancer For over 50 years, the primary form of therapy for advanced prostate cancer has targeted the androgen receptor. However, there have been few cures and virtually all patients with metastatic prostate cancer treated with androgen...

...A.L. Parrill Lysophosphatidic acid (LPA; 1-acyl-3-phosphoglycerol) exerts its biological activity through both extracellular and intracellular targets. Receptor targets include the cell-surface G-protein-coupled receptors LPA 1–4 and the nuclear PPAR-γ (peroxisome-proliferator-activated receptor γ...

... and/or have ‘receptor-like’ activity [ 19 ] and/or as regulators of LPPs (see below). apoptosis lipid phosphate phosphatase (LPP) lysophosphatidic acid (LPA) signalling sphingosine 1-phosphate (S1P) sphingosine kinase (SK) Mammalian LPPs (lipid phosphate phosphatases) are integral membrane...

... 2003 Biochemical Society 2003 cytoskeleton lysophosphatidic acid (LPA) motility phospholipase Rho GTPase Tiam1 Abbreviations used: LPA, lysophosphatidic acid; GPCR, G-protein-coupled receptor; PI 3-kinase, phosphoinositide 3-kinase; EGF, epidermal growth factor; PLD, phospholipase...